BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36988829)

  • 1. RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines.
    Shang S; Chen Y; Yang X; Yang Y; Wang W; Wang Y
    Invest New Drugs; 2023 Apr; 41(2):220-225. PubMed ID: 36988829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
    Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
    Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
    Sterner RM; Cox MJ; Sakemura R; Kenderian SS
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.
    Dibas A; Rhiel M; Patel VB; Andrieux G; Boerries M; Cornu TI; Alzubi J; Cathomen T
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways.
    Liu L; Cheng Y; Zhang F; Chen J; Tian P; Shi W; Zhou F; Yang M; Zhou M; Liu B
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5547-5557. PubMed ID: 36474002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
    Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
    J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome.
    Jiang Y; Feng D; Wang C; Zhang Y; Zhao C; Li S; Qin Y; Chang AH; Zhu J
    Front Med (Lausanne); 2022; 9():1042501. PubMed ID: 36405594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
    Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding the dendritic cell lineage through a study of cytokine receptors.
    Kämpgen E; Koch F; Heufler C; Eggert A; Gill LL; Gillis S; Dower SK; Romani N; Schuler G
    J Exp Med; 1994 Jun; 179(6):1767-76. PubMed ID: 8195707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
    Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
    J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
    Xu C; Yin Y
    Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed T
    Xhangolli I; Dura B; Lee G; Kim D; Xiao Y; Fan R
    Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):129-139. PubMed ID: 31229590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release.
    Oehler L; Foedinger M; Koeller M; Kollars M; Reiter E; Bohle B; Skoupy S; Fritsch G; Lechner K; Geissler K
    Blood; 1997 Feb; 89(4):1147-53. PubMed ID: 9028936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
    Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
    Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
    Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.